Developing siRNA Therapies: A Technical Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Developing siRNA Therapies: A Technical Forum
Pharmaceutical Technology talked to experts in siRNA-drug development to gain insight into the characteristics, processes, and challenges of this class of therapeutics.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 39-41




Small interfering RNA (siRNA) therapies are a type of RNA-interfering drugs (RNAi) that have shown to be effective at silencing genes in preclinical and clinical studies. Unlike biologically based gene therapy treatments, synthetic siRNA therapeutics can be manufactured under completely controlled conditions. They are considered to be large small-molecule therapies and, therefore, follow the established regulatory pathway for those types of drugs. As clinical trials for siRNA therapies continue to advance toward approvals for this class of drugs, Pharmaceutical Technology asked leading companies about their work in this emerging field.

Representatives from Alnylam Pharmaceuticals (Cambridge, MA), MDRNA (Bothell, WA), and Quark Pharmaceuticals (Fremont, CA) discuss their approaches and techniques for developing and delivering siRNA therapeutics, specifically, liposomal and naked siRNA delivery. Participants in the forum are Mark Tracy, PhD, senior director of pharmaceutical operations at Alnylam Pharmaceuticals; Michael Houston, vice-president of chemistry and formulations at MDRNA; and James Thompson, vice-president of pharmaceutical development at Quark Pharmaceuticals.

PharmTech: What novel approaches is your company taking to deliver siRNA therapies?

Tracy (Alnylam): Dosage forms for systemic delivery of siRNA must meet several important criteria. In particular, they must maintain drug stability, enable transport of the siRNA through the body to the desired organ and cell type(s) within that organ, and, then, allow transport of the siRNA to the cytoplasm within the desired target cells.

Novel lipid nanoparticle (LNP) formulations containing specially designed lipids are one of the few siRNA delivery systems to date that have demonstrated highly potent silencing in vivo of multiple targets in multiple species, including non-human primates. These formulations are able to overcome the delivery challenges described above.

LNP formulations can be designed to achieve silencing of target genes in a variety of cell types in the liver, tumors, and immune cells, among other cell types and tissues. LNP formulations that have advanced to the clinic to date are specifically designed for delivery to cell types in the liver, including hepatocytes and tumor cells.

Houston (MDRNA): MDRNA is developing liposome formulations based on its DiLA2 (di-alkylated amino acid) platform. This platform allows MDRNA to create a library of DiLA2 molecules, and subsequent formulations for delivery of siRNA, where key characteristics such as charge, fusogenicity, and pH responsiveness can be tailored to meet the delivery requirements associated with specific therapeutic indications. MDRNA has formulations for systemic and local delivery.



Formulations currently in development do not use active targeting moieties, but this is a focused area of our research. The DiLA2 platform readily enables the incorporation of peptide, protein, and other classes of targeting ligands. MDRNA has developed a proprietary phage display library based on the [self-folding mini proteins called a Trp cage peptide] as a source of novel, highly specific targeting agents.

Thompson (Quark): We have not devoted our initial efforts toward liposomal delivery. Quark's strategy has been, with synthetic siRNAs, to evaluate what cell types take up the siRNAs and where they distribute after various routes of administration. For example, when you administer our type of siRNAs intravenously, they are rapidly cleared by the kidneys and distribute almost exclusively to the kidney. Because of this, we are focusing one program on kidney indications. We're basically going where the siRNAs go. Formulations allow you to change the distribution and to lower the dose of the siRNA to gain more efficient delivery with certain delivery vehicles. There's always a tradeoff, however, when developing formulations in terms of the cost:benefit ratio.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here